What the FDA labels say about taking them together
Ketorolac and tromethamine
Ketorolac's FDA label of August 31, 2023 names tromethamine in its boxed warning section; the tromethamine label PlainMeds reads does not name ketorolac. The ketorolac label: “CONTRAINDICATIONS (see also Boxed WARNING ) Ketorolac Tromethamine is contraindicated in patients with previously demonstrated hypersensitivity to ketorolac tromethamine.”
Check it at the source: the ketorolac FDA label on DailyMed (effective August 31, 2023, Fresenius Kabi USA, LLC); the tromethamine FDA label on DailyMed (effective May 27, 2026, Hospira, Inc.).
What does the ketorolac label say about tromethamine?
Ketorolac label, boxed warningWARNING Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the short-term (up to 5 days in adults) management of moderately severe acute pain that requires analgesia at the opioid level.
Ketorolac label, contraindicationsCONTRAINDICATIONS (see also Boxed WARNING ) Ketorolac Tromethamine is contraindicated in patients with previously demonstrated hypersensitivity to ketorolac tromethamine.
Ketorolac label, drug interactionsThere is no evidence in animal or human studies that ketorolac tromethamine induces or inhibits hepatic enzymes capable of metabolizing itself or other drugs.
Ketorolac label, warningsThe most serious risks associated with ketorolac tromethamine are: Gastrointestinal Effects – Risk of Ulceration, Bleeding and Perforation:
Acular label (Allergan, Inc., September 18, 2025), warnings and precautionsThere have been reports of bronchospasm or exacerbation of asthma associated with the use of ketorolac tromethamine ophthalmic solution in patients who have either a known hypersensitivity to aspirin/non-steroidal anti-inflammatory drugs or a past medical history of asthma.
Ketorolac Tromethamine label (Pacific Pharma, Inc., June 21, 2024), contraindicationsCONTRAINDICATIONS Ketorolac tromethamine ophthalmic solution is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formulation [see Adverse Reactions (6.1) ].
Source: FDA drug label (Ketorolac Tromethamine), Fresenius Kabi USA, LLC, effective August 31, 2023 (SPL set 3d88cbe6-5230-47aa-80af-0c41283d1f00), via openFDA; the full label on DailyMed
What does the tromethamine label say about ketorolac?
Tromethamine's label (effective May 27, 2026) does not name ketorolac in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (THAM), Hospira, Inc., effective May 27, 2026 (SPL set 4af52118-c12b-4ad5-30bb-959848357e8a), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Ketorolac | Tromethamine | |
|---|---|---|
| Labeled for | Pain | n/a |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $1.02 per mL 30 mg/mL vial | n/a |
| Shortage now | In shortage | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once